Residual flow may increase the risk of adverse events in patients received combined catheter ablation and transcatheter left atrial appendage closure for nonvalvular atrial fibrillation: a meta-analysis.
Zhonglin HanXiang WuZheng ChenWengqing JiXuehua LiuYu LiuWencheng DiXiaohong LiHongsong YuXinlin ZhangBiao XuRong Fang LanWei XuPublished in: BMC cardiovascular disorders (2019)
Bleeding events were more common in patients with a higher procedural residual flow event rate. However, combined CA and LAAC therapy is reasonably safe and efficacious in patients with nonvalvular AF. Further studies on the safety and efficacy of CA or LAAC alone are necessary in future.
Keyphrases
- atrial fibrillation
- left atrial appendage
- catheter ablation
- left atrial
- oral anticoagulants
- direct oral anticoagulants
- end stage renal disease
- heart failure
- ejection fraction
- percutaneous coronary intervention
- newly diagnosed
- chronic kidney disease
- protein kinase
- peritoneal dialysis
- stem cells
- current status
- patient reported outcomes
- cell therapy
- prognostic factors
- smoking cessation
- acute coronary syndrome